Novel biologic approaches to hematologic malignancies

  • Janice P. Dutcher
  • Peter H. Wiernik
Part of the Cancer Treatment and Research book series (CTAR, volume 99)


Normal hematopoiesis and lymphopoiesis are dependent upon the interactions of a broad array of endogenous cytokines that have both positive and negative influences on proliferation and differentiation of these tissues. Many hematologic malignancies demonstrate aberrant growth or differentiation or both, yet appear to retain their ability in part to respond to normal regulatory molecules. Therefore, over the course of the past 20 years, attempts have been made to utilize regulatory cytokines to control hematologic malignancies. In certain instances, such as interferon therapy for hairy cell leukemia, this attempt has been quite successful, and in other situations we are still exploring the possibilities. Nevertheless, there appears to be a potential for growth control if not disease eradication through the utilization of biologic therapy in hematologic malignancies.


Multiple Myeloma Acute Myeloid Leukemia Chronic Myeloid Leukemia Myelodysplastic Syndrome Acute Promyelocytic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bergsagel DE, Haas RH, Messner HA. 1986. Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 13:29–34.PubMedGoogle Scholar
  2. 2.
    Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU. 1986. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to α-Interferon: correlation with receptor binding and induction of 2’,5’-oligoadenylate synthetase. Cancer Res 46:4848–4852.PubMedGoogle Scholar
  3. 3.
    Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. 1994. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired B1 integrin receptor function. J Clin Invest 94:384–391.PubMedGoogle Scholar
  4. 4.
    Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. 1987. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280–1288.PubMedGoogle Scholar
  5. 5.
    Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. 1986. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314:1065–1069.PubMedGoogle Scholar
  6. 6.
    Alimena G, Morra E, Lazzarino M, et al. 1988. Interferon alpha-2b as therapy for Ph1-positive chronic myelogenous leukemia. A study of 82 patients treated with intermittent or daily administration. Blood 72:642–647.PubMedGoogle Scholar
  7. 7.
    Ozer H, George SL, Schiffer CA, et al. 1993. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82:2975–2984.PubMedGoogle Scholar
  8. 8.
    Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. 1991. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 114:532–538.PubMedGoogle Scholar
  9. 9.
    Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. 1993. Chronic myelogenous leukemia: a concise update. Blood 82:691–703.PubMedGoogle Scholar
  10. 10.
    Tura S, and the Italian Cooperative Study Group of Chronic Myeloid Leukemia. 1994. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820–825.Google Scholar
  11. 11.
    Hehlmann R, Heimpel H, Hasford J, et al. and the German CML Study Group. 1994. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064–4077.PubMedGoogle Scholar
  12. 12.
    Ohnishi K, Ohno R, Tomonaga M, et al. and the Kouseisho Leukemia Study Group. 1995. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906–916.PubMedGoogle Scholar
  13. 13.
    Allan NC, Richards SM, Shepherd PCA, and UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. 1995. UK Medical Research Council randomized, multicentre trial of interferon-αnl for chronic myeloid leukaemia is not confined to patients with cytogenetic response: improved survival irrespective of cytogenetic response. Lancet 345:1392–1397.PubMedGoogle Scholar
  14. 14.
    Coletti D, Dutcher JP, Paietta E, Wiernik PH. 1992. Alpha interferon + plicamycin for accelerated phase chronic myelogenous leukemia. Blood 80(Suppl l):211a.Google Scholar
  15. 15.
    Bourantas KL, Syrou M, Tsiara S, Danella M, Konstantinides P. 1996. Combination therapy with interferon alfa-2b and hydroxyurea during the accelerated phase of chronic myelogenous leukemia. Acta Haematol 95:117–121.PubMedGoogle Scholar
  16. 16.
    Guilhot F, Lamagnere JP, Harousseau JL, Tilly H, Casassus P, Ifrah N, Rochant H, Bauters F, Dine G, Tanzer J. 1991. A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside, preliminary results. Eur J Cancer 27(Suppl 4):S26.PubMedGoogle Scholar
  17. 17.
    Kantarjian HM, Keating MJ, Estey EH, O’Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. 1992. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J Clin Oncol 10:772–779.PubMedGoogle Scholar
  18. 18.
    Riedel D, Lindemann A, Otto J, Brennscheidt U, Lubbert M, Mertelsmann R, Herrmann F. 1990. Gamma-interferon interrupts growth stimulation in chronic myelogenous leukemia established by endogenous granulocyte colony-stimulating factor. Leukemia 11:786–789.Google Scholar
  19. 19.
    Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. 1987. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70:943–947.PubMedGoogle Scholar
  20. 20.
    Kloke O, Wandl U, Opalka B, Moritz T, Nagel-Hiemke M, Franz T, Becher R, Hirche H, Seeber S, Niederle N. 1992. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukemia. Eur J Haematol 48:93–98.PubMedGoogle Scholar
  21. 21.
    Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. 1991. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer 68:2125–2129.PubMedGoogle Scholar
  22. 22.
    Huang M-e, Ye Y-c, Chen S-r, Chai J-r, Lu J-x, Lin Z, Gu L-j, Wang Z-y. 1988. Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–572.PubMedGoogle Scholar
  23. 23.
    Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. 1990. All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704–1711.PubMedGoogle Scholar
  24. 24.
    Wiernik PH, Dutcher JP, Paietta E, Hittleman WN, Vyas R, Strack M, Castaigne S, Degos L, Gallagher RE. 1991. Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all trans retinoic acid. Leukemia 5:504–509.PubMedGoogle Scholar
  25. 25.
    Sagayadan GE, Wiernik PH, Sun N, Ahearn G, Thompson D, Hallam SJ, Hu X.-p, Dutcher JP, Gallagher RE. 1994. Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: increased inhibition by all-trans- and 12-cis-retinoic acids in advanced stage disease. Leuk Res 18:741–746.PubMedGoogle Scholar
  26. 26.
    Gallagher RE, Lurie KJ, Leavitt RD, Wiernik PH. 1987. Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-aA interferon. Leuk Res 11:609–613.PubMedGoogle Scholar
  27. 27.
    Collins RH Jr, Rogers ZR, Bennett M, Kumar V, Nikein A, Fay JW. 1992. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 10:391–395.PubMedGoogle Scholar
  28. 28.
    Kolb HJ, Mittermuller J, Clemm CH, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465.PubMedGoogle Scholar
  29. 29.
    Cullis JO, Jiang YZ, Schwarere AP, Hughes TP, Barrett AJ, Goldman JM. 1992. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79:1379–1380.PubMedGoogle Scholar
  30. 30.
    Drobyski WR, Keever CA, Roth MS, et al. 1993. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82:2310–2318.PubMedGoogle Scholar
  31. 31.
    Porter DL, Roth MS, Mcgarigle C, Ferrara JLM, Antin JH. 1994. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330: 100–106.PubMedGoogle Scholar
  32. 32.
    Mackinnon S, Papadopoulos EB, Carabasi MH, et al. 1995. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261–1268.PubMedGoogle Scholar
  33. 33.
    Byzyn-Veil A, Belanger C, Audat F, et al. 1996. Sustained complete cytologic and molecular remission induced by donor leucocyte infusions alone in an acute myeloblastic leukaemia in relapse after bone marrow transplantation. Br J Haematol 92:423–425.Google Scholar
  34. 34.
    Estrov Z, Lau AS, Williams BRG, Freedman MH. 1987. Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction and growth suppression in vitro. Exp Hematol 15:127–132.PubMedGoogle Scholar
  35. 35.
    Castleberry RP, Emanuel PD, Zuckerman KS, Cohn S, Strauss L, Byrd RL, Homans A, Chaffee S, Nitxchke R, Gualtieri RJ. 1994. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 331:1680–1684.PubMedGoogle Scholar
  36. 36.
    Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. 1991. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 78:1478–1483.Google Scholar
  37. 37.
    Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M. 1994. Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood 84:3142–3149.PubMedGoogle Scholar
  38. 38.
    Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R, Estey EH, Talpaz M. 1995. Effect of interleukin-lβ converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood 86:4594–4602.PubMedGoogle Scholar
  39. 39.
    Ghezzi P, Dinarello CA. 1988. IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-gamma. J Immunol 140:4238–4244.PubMedGoogle Scholar
  40. 40.
    Heslop HE, Bianchi ACM, Cordingley FT, Turner M, DeMel WCP, Hoffbrand AV, Brenner MK. 1990. Effects of interferon-α on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med 172:1729–1735.PubMedGoogle Scholar
  41. 41.
    Smith KA. 1988. Interleukin-2: inception, impact, and implications. Science 240:1169–1172.PubMedGoogle Scholar
  42. 42.
    Ruscetti FW, Morgan DA, Gallo RC. 1977. Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol 119:131–137.PubMedGoogle Scholar
  43. 43.
    Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. 1984. Response of resting human peripheral blood natural killer cells to interleukin-2. J Exp Med 160:1147–1152.PubMedGoogle Scholar
  44. 44.
    Dawson MM, Johnston D, Taylor GM, Moore M. 1986. Lymphokine activated killing of fresh human leukaemias. Leuk Res 10:683–688.PubMedGoogle Scholar
  45. 45.
    Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H. 1986. Cytotoxicity of interleukin-2-activated lymphocytes for leukemia and lymphoma cells. Blood 68:938–948.PubMedGoogle Scholar
  46. 46.
    Fiero MT, Liao X-s, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R. 1988. In vitro and in vivo susceptibility of human leukemia cells to lymphokine activated killer activity. Leukemia 2:50–54.Google Scholar
  47. 47.
    Teichmann JV, Ludwig W-d, Seibt-Jung H, Thiel E. 1989. Induction of lymphokine-activated killer cells against human leukemia cells in vitro. Blut 59:21–24.PubMedGoogle Scholar
  48. 48.
    Archimbaud EL, Thomas X, Campos L, Magaud J-P, Fiere D, Dore J-F. 1991. Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells. Leukemia 5:967–971.PubMedGoogle Scholar
  49. 49.
    Findley HW Jr, Mageed AA, Nasr SA, Ragab AH. 1988. Recombinant interleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells. Cancer 62:1928–1931.PubMedGoogle Scholar
  50. 50.
    Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB. 1988. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:709–716.PubMedGoogle Scholar
  51. 51.
    Foa R, Guarini A, Tos AG, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F. 1991. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin-2: evidence of in vivo lymphokine activated killer cell generation. Cancer Res 51:964–968.PubMedGoogle Scholar
  52. 52.
    Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F, Mandelli F. 1991. Treatment of acute myeloid leukaemia patients with recombinant interleukin-2: a pilot study. Br J Haematol 77:491–496.PubMedGoogle Scholar
  53. 53.
    Maraninchi D, Blaise D, Viens P, et al. 1991. High dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78:2182–2187.PubMedGoogle Scholar
  54. 54.
    Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F. 1994. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84:2158–2163.PubMedGoogle Scholar
  55. 55.
    Gottlieb DJ, Brenner MK, Heslop HE, et al. 1989. A phase I clinical trial of recombinant interleukin-2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 60:610–615.PubMedGoogle Scholar
  56. 56.
    Wiernik PH, Dutcher JP, Todd M, Caliendo G, Benson L. 1994. Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematol 47:41–44.PubMedGoogle Scholar
  57. 57.
    Bergmann L, Heil G, Kolbe K, Lengfelder E, Puzicha E, Martin H, Lohmeyer J, Mitrou PS, Holzer D. 1995. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 16:271–279.PubMedGoogle Scholar
  58. 58.
    Macdonald D, Jiang Y, Gordon AA, Mahendra P, Oskam R, Palmer PA, Franks CR, Barrett AJ. 1990. Recombinant interleukin-2 for acute myeloid leukaemia in first complete remission: a pilot study. Leuk Res 14:967–973.PubMedGoogle Scholar
  59. 59.
    Macdonald D, Jiang YZ, Swirsky D, Vulliamy T, Morilla R, Bungey J, Barrett AJ. 1991. Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor. Br J Haematol 77:43–49.PubMedGoogle Scholar
  60. 60.
    Spiekermann K, O’Brien S, Estey E. 1995. Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Cancer 75:1594–1597.PubMedGoogle Scholar
  61. 61.
    Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspina H, O’Reilly RJ, Keever CA. 1990. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250–2262.PubMedGoogle Scholar
  62. 62.
    Sykes M, Abraham VS, Harty MW, Pearson DA. 1993. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4 + T cell activity. J Immunol 150:197–205.PubMedGoogle Scholar
  63. 63.
    Charak BS, Agah R, Mazumder A. 1992. Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation. Blood 80:179–184.PubMedGoogle Scholar
  64. 64.
    Nierle T, Bunjes D, Arnold R, Heimpel H, Theobald M. 1993. Quantitative assessment of posttransplant host-specific interleukin-2-secreting T-helper cell precursors in patients with or without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation. Blood 81:841–848.PubMedGoogle Scholar
  65. 65.
    Sykes M, Harty MW, Szot GL, Pearson DA. 1994. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4 + cells while preserving CD4-and CD8-mediated graft-versus leukemia effects. Blood 83:2560–2569.PubMedGoogle Scholar
  66. 66.
    Champlin R. 1995. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Exp Hematol 23:1148–1151.PubMedGoogle Scholar
  67. 67.
    Charak BS, Brynes RK, Groshen S, Chen SC, Mazumder A. 1990. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76:2187–2190.PubMedGoogle Scholar
  68. 68.
    Charak BS, Brynes RK, Katsuda S, Groshen S, Chen SC, Mazumder A. 1991. Induction of graft vs. leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin-2 therapy. Cancer Res 51:2015–2020.PubMedGoogle Scholar
  69. 69.
    Kloosterman TC, Martens ACM, Osterwalder B, Hagenbeek A. 1994. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML. Bone Marrow Transplant 14:965–973.PubMedGoogle Scholar
  70. 70.
    Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK. 1989. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73:1351–1358.PubMedGoogle Scholar
  71. 71.
    Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK. 1989. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood 74:2335–2342.PubMedGoogle Scholar
  72. 72.
    Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. 1991. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 77:2561–2568.PubMedGoogle Scholar
  73. 73.
    Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J. 1992. Clinical and immunological effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79:517–526.PubMedGoogle Scholar
  74. 74.
    Antin JH, Ferrara JLM. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964–2968.PubMedGoogle Scholar
  75. 75.
    Vogelsang GB, Hess AD. 1994. Graft-versus-host disease: new directions for a persistent problem. Blood 84:2061–2067.PubMedGoogle Scholar
  76. 76.
    Klingemann H-G, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepherd JD, Sutherland HJ, Phillips GL. 1994. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 14:389–396.PubMedGoogle Scholar
  77. 77.
    Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A. 1993. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12:159–163.PubMedGoogle Scholar
  78. 78.
    Soiffer RJ, Murray C, Gonin R, Ritz J. 1994. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964–971.PubMedGoogle Scholar
  79. 79.
    Klingemann H-G, Phillips GL. 1995. Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia. Leuk Lymphoma 16:397–405.PubMedGoogle Scholar
  80. 80.
    Kalland T. 1990. Regulation of natural killer progenitors. Studies with a novel immuno-modulator with distinct effects at the precursor level. J Immunol 144:4472–4478.PubMedGoogle Scholar
  81. 81.
    Kalland T, Maksimova A, Stalhandske T. 1985. Prophylaxis and treatment of experimental tumors with the immunomodulator LS2616. Int J Immunopharmacol 7:390–396.Google Scholar
  82. 82.
    Bengtsson M, Simonsson B, Carlsson K, et al. 1992. Stimulation of NK cell, T cell and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 53:882–890.PubMedGoogle Scholar
  83. 83.
    Rowe JM, Nilsson BI, Simonsson B, Bengtsson M. 1993. Treatment of minimal residual disease in myeloid leukemia: the immunotherapeutic options with emphasis on linomide. Leuk Lymphoma 11:321–329.PubMedGoogle Scholar
  84. 84.
    Ishizuka M, Masuda T, Kanbayashi N, Fukasawa S, Takeuchi T, Aoyagi T, Umezawa H. 1980. Effect of bestatin on mouse immune system and experimental murine tumors. J Antibiot 33:642–649.PubMedGoogle Scholar
  85. 85.
    Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N. 1986. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother 23:5–10.PubMedGoogle Scholar
  86. 86.
    Urabe A, Mutoh Y, Mizoguchi H, Takaku F, Ogawa N. 1993. Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol 67:63–66.PubMedGoogle Scholar
  87. 87.
    Kobayashi T, Miyawaki S, Tanimoto M, et al., for the Japan Adult Leukemia Study Group. 1996. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol 14:204–213.PubMedGoogle Scholar
  88. 88.
    Scheinberg DA, Lovett D, Divgi CR, et al. 1991. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478–490.PubMedGoogle Scholar
  89. 89.
    Schwartz MA, Lovett DR, Redner A, et al. 1993. Dose-escalation trial of M195 labeled with Iodine-131 for cytoreduction and marrow ablation in relapsed and refractory myeloid leuke-mias. J Clin Oncol 11:294–303.PubMedGoogle Scholar
  90. 90.
    Sgouros G, Graham MC, Divgi CR. 1993. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med 34:422–430.PubMedGoogle Scholar
  91. 91.
    Jurcic JG, Caron PC, DeBlasio A, Dumont L, Warrell RP Jr, Scheinberg DA. 1995. Targeted therapy with humanized anti-CD33 monoclonal antibody (HuM195) reduces residual disease in acute promyelocytic leukemia. Blood 86(Suppl l):517a. (abstract)Google Scholar
  92. 92.
    Metcalf D. 1989. The molecular control of cell division, differentiation commitment and maturation in haematopoietic cells. Nature 339:27–33.PubMedGoogle Scholar
  93. 93.
    Sachs L. 1990. The control of growth and differentiation in normal and leukemic blood cells. Cancer 65:2196–2202.PubMedGoogle Scholar
  94. 94.
    Jacobs A. 1991. Genetic lesions in preleukemia. Leukemia 5:277–282.PubMedGoogle Scholar
  95. 95.
    Janssen JWG, Buschle M, Layton M, Drexler HG, Lyons J, van den Berghe H, Heimpel H, Kubanek B, Kleihauer E, Mufti GJ. 1989. Clonal analysis of myelodysplastic syndromes: evidence of multipotential stem cell origin. Blood 73:248–352.PubMedGoogle Scholar
  96. 96.
    Merchav S, Nagler A, Fleischer-Kurtz G, Tatarsky I. 1989. Regulatory abnormalities in the marrow of patients with myelodysplastic syndromes. Br J Haematol 73:158–164.PubMedGoogle Scholar
  97. 97.
    Merchav S, Wagemaker G, Souza LM, Tatarsky I. 1991. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 4:340–346.Google Scholar
  98. 98.
    Ganser A, Hoelzer D. 1992. Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol Oncol Clin North Am 6:633–653.PubMedGoogle Scholar
  99. 99.
    Schuster MW, Larson RL, Thompson JA. 1990. Granulocyte macrophage-colony stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): results of a multi-center randomized controlled trial. Blood 76(Suppl 1): 3189a. (abstract)Google Scholar
  100. 100.
    Stein RS, Abels RI, Krantz SB. 1991. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78:1658–1663.PubMedGoogle Scholar
  101. 101.
    Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herrmann F, Eder M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D. 1990. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666–672.PubMedGoogle Scholar
  102. 102.
    Ganser A, Seipelt G, Lindemann A, Ottmann OG, Falk S, Eder M, Herrmann F, Becher R, Hoffken K, Buchner T. 1990. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455–462.PubMedGoogle Scholar
  103. 103.
    Dunbar CE, Smith D, Kimball J, Garrison L, Nienhuis AW, Young NS. 1990. Sequential treatment with recombinant human growth factors to compare activity of GM-CSF and IL3 in the treatment of primary myelodysplasia. Blood 76(Suppl l):141a. (abstract)Google Scholar
  104. 104.
    Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. 1991. Phase I study of recombinant interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250.PubMedGoogle Scholar
  105. 105.
    Orazi A, Cooper RJ, Tong J, et al. In press. Effects of recombinant human interleukin eleven (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol.Google Scholar
  106. 106.
    Tepler I, Elias L, Smith JW II, et al. 1996. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607–3614.PubMedGoogle Scholar
  107. 107.
    Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. 1996. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615–3624.PubMedGoogle Scholar
  108. 108.
    Farese AM, Hunt P, Grab LB, MacVittie TJ. 1995. Evaluation of administration protocols of pegylated-megakaryocyte growth and development factor on platelet recovery in a primate model of radiation-induced bone marrow aplasia. Blood 86(Suppl l):497a. (abstract)Google Scholar
  109. 109.
    Harker LA, Marzek UM, Kelly AB, Hanson SR. 1995. Enhanced hematopoietic regeneration in primate model of myelosuppressive chemotherapy by pegylated recombinant human megakaryocyte growth and development factor in combination with granulocyte colony stimulating factor. Blood 86(Suppl l):497a. (abstract)Google Scholar
  110. 110.
    Rasko JEF, Basser R, O’Malley CJ, et al. 1995. In vitro studies from a phase I randomized, blinded trial of pegylated megakaryocyte growth and development factor. Blood 86(Suppl l):497a. (abstract)Google Scholar
  111. 111.
    Neelis KJ, Wognum AW, Eaton D, Thomas R, Wagemaker G. 1995. Preclinical evaluation of thrombopoietin in rhesus monkeys. Blood 86(Suppl l):256a. (abstract)Google Scholar
  112. 112.
    Murray LJ, Luens KM, Bruno E, Ho A, Brandt J, Hoffman R, Young J. 1995. The effects of thrombopoietin on human hematopoietic stem cells. Blood 86(Suppl l):256a. (abstract)Google Scholar
  113. 113.
    Matsumura I, Kanakura Y, Ikeda H, Ishikawa J, Kitayama H, Tahar T, Kato T, Miyazaki H, Matsuzawa Y. 1995. Functional role of thrombopoietin in the abnormal growth of acute myeloblastic leukemia cells. Blood 86(Suppl l):20a. (abstract)Google Scholar
  114. 114.
    Verbeek W, Faulhaber M, Vehmeyer K, Haase D, Hiddemann W. 1995. In vitro response of normal myelodysplastic megakaryopoiesis to megakaryocyte growth and development factor. Blood 86(Suppl l):20a. (abstract)Google Scholar
  115. 115.
    Aul C, Runde V, Gattermann N. 1993. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 82:2967–2974.PubMedGoogle Scholar
  116. 116.
    Kurzrock R, Estey E, Talpaz M. 1993. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 11:1489–1496.PubMedGoogle Scholar
  117. 117.
    Besa EC, Abrahm JL, Bartholomew MJ, Hyzinski M, Nowell PC. 1990. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. Am J Med 89:739–747.PubMedGoogle Scholar
  118. 118.
    Clark RE, Ismail SAD, Jacobs A, Payne H, Smith SA. 1987. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with myelodysplastic syndrome. Br J Haematol 66:77–83.PubMedGoogle Scholar
  119. 119.
    Picozzi VJ Jr, Swanson GF, Morgan R, Hecht F, Greenberg PL. 1986. 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 4:589–595.PubMedGoogle Scholar
  120. 120.
    Koeffler HP, Heitjan D, Mertelsmann R, Kolitz JE, Schulman P, Itri L, Gunter P, Besa E. 1988. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood 71:703–708.PubMedGoogle Scholar
  121. 121.
    De Witte T, Muus P, DePauw B, Haanen C. 1990. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831–837.PubMedGoogle Scholar
  122. 122.
    Aul C, Schneider W. 1990. Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy? Haematol Blood Transfus 33:382–385.PubMedGoogle Scholar
  123. 123.
    Rowe J, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH. 1995. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457–462.PubMedGoogle Scholar
  124. 124.
    Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Gutterman JU. 1986. Treatment of multiple myeloma with recombinant α-interferon. Blood 67:275–278.PubMedGoogle Scholar
  125. 125.
    Montuoro A, DeRosa L, DeBlasio A, Pacilli L, Petti N, de Laurenzi A. 1990. Alpha-2a-interferon/melphalan/ prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 76:365–368.PubMedGoogle Scholar
  126. 126.
    Hjorth M and the Nordic Myeloma Study Group. 1996. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in myeloma. Ann Intern Med 124:212–222.Google Scholar
  127. 127.
    Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, Bernhardt B, Duggan D, Faragher D, Schiffer C. 1993. A randomized clinical trial comparing melphalan/ prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 11:155–160.PubMedGoogle Scholar
  128. 128.
    Salmon SE, Durie BG, Young L, Liu RM, Trown PW. 1983. Effects of cloned leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217–222.PubMedGoogle Scholar
  129. 129.
    Brenning G. 1985. The in vitro effects of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 35:178–184.PubMedGoogle Scholar
  130. 130.
    Mandelli F, Avvisati G, Amadori S, et al. 1990. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430–1434.PubMedGoogle Scholar
  131. 131.
    Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. 1995. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 89:561–568.PubMedGoogle Scholar
  132. 132.
    Browman GP, Bergsagel D, Sicheri D, et al. 1995. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13:2354–2360.PubMedGoogle Scholar
  133. 133.
    Ludwig H, Cohen AM, Huber H, Senn H, Gunczler P, Schuller J, Eckhardt S, Seewann HL, Cavalli F, Fritz E. 1994. Interferon alfa-2b with VMCP compared to VMCP for induction and interferon alfa-2b compared to control for remission maintenance in multiple myeloma. Proc Am Soc Clin Oncol 13:408.Google Scholar
  134. 134.
    Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. 1994. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 12:2405–2414.PubMedGoogle Scholar
  135. 135.
    Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun HJ, Fett W, Fischer JT, Gobel B. 1995. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon alpha for maintenance treatment, in multiple myeloma. A prospective study of the German Myeloma Treatment Group. Eur J Cancer 31 A:146–151.Google Scholar
  136. 136.
    Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA. 1995. Epoetin alfa for the treatment of the anemia of multiple myeloma. Arch Intern Med 155:2069–2074.PubMedGoogle Scholar
  137. 137.
    Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D, for the European Study Group of Erythropoietin Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. 1996. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma — A randomized multicenter study. Blood 87:2675–2682.PubMedGoogle Scholar
  138. 138.
    Peest D, Leo R, Bloche S, et al. 1995. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Br J Haematol 89:328–337.PubMedGoogle Scholar
  139. 139.
    Wiernik PH, Dutcher JP, Leaf AN, Liao Z, Paietta E, Rosenstreich DL. 1994. Objective response of multiple myeloma to cyclosporin A. Leuk Lymphoma 16:167–171.PubMedGoogle Scholar
  140. 140.
    Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H. 1988. Autocrine generation and requirement of BSF-2/IL6 for human multiple myelomas. Nature 332:83–85.PubMedGoogle Scholar
  141. 141.
    Klein B, Zhang X-G, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. 1989. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 73:517–526.PubMedGoogle Scholar
  142. 142.
    Lapena P, Prieto A, Garcia-Suarez J, Reyes E, San Miguel J, Jorda J, Alvarez-Mon M. 1996. Increased production of interleukin-6 by T lymphocytes from patients with multiple myeloma. Exp Hematol 24:26–30.PubMedGoogle Scholar
  143. 143.
    Kimchi A. 1992. Cytokine triggered molecular pathways that control cell cycle arrest. J Cell Biochem 50:1–7.PubMedGoogle Scholar
  144. 144.
    Sreevalsan T. 1995. Biologic therapy with interferon-α and: preclinical studies. In: DeVita VT, Rosenberg S, Hellman S (eds), Biologic Therapy in Cancer, 3rd ed. J P. Lippincott: Philadelphia, pp 347–364.Google Scholar
  145. 145.
    Ratain MJ, Golomb HM, Vardiman JW. 1985. Treatment of hairy cell leukemia with recombinant alpha2 interferon. Blood 65:644–648.PubMedGoogle Scholar
  146. 146.
    Golomb HM, Ratain MJ, Mick R, Daly K. 1992. Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983–1986. Leukemia 6:1177–1180.PubMedGoogle Scholar
  147. 147.
    Gill PS, Harrington W Jr, Kaplan MH, et al. 1995. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332:1744–1748.PubMedGoogle Scholar
  148. 148.
    Hermine O, Bouscary D, Gessain A, et al. 1995. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332:1749–1751.PubMedGoogle Scholar
  149. 149.
    Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC. 1981. Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. Blood 58:712–718.PubMedGoogle Scholar
  150. 150.
    O’Connell MJ, Colgan JP, Oken MM, Ritts RE Jr, Kay NE, Itri LM. 1986. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukemia: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 4:128–136.PubMedGoogle Scholar
  151. 151.
    Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O’Connell MJ, Oken MM, Borden EC. 1992. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 327:1336–1241.PubMedGoogle Scholar
  152. 152.
    Andersen JW, Smalley RV. 1993. Interferon alfa plus chemotherapy for non-Hodgkin’s lymphoma: five-year follow-up. N Engl J Med 329:1821–1822.PubMedGoogle Scholar
  153. 153.
    Solal-Celigny P, Lepage E, Brousse N, et al., for the Groupe d’Etude des Lymphomes de l’Adulte. 1993. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608–1614.PubMedGoogle Scholar
  154. 154.
    Unterhalt M, Hermann R, Koch P, et al., for the German Low Grade NHL Study Group. 1996. Significant prolongation of disease free interval in advanced low grade non-Hodgkin lymphomas by interferon alpha maintenance and its relation to initial cytoreductive treatment. Ann Oncol 7(Suppl 3): 55.Google Scholar
  155. 155.
    Hagenbeek A, Carde P, Somers R, Thomas J, de Bock R, Raemaekers J, van Hoof A, van Glabbeke M, Meerwaldt JH. for the EORTC Lymphoma Cooperative Group. 1992. Maintenance of remission with human recombinant alpha-2 interferon (Roferon-A) in patients with stages III and IV low-grade malignant non-Hodgkin’s lymphoma: results from a prospective, randomized Phase III clinical trial in 331 patients. Blood 80(Suppl 1):288A. (abstract)Google Scholar
  156. 156.
    Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. 1992. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin’s lymphoma. J Clin Oncol 10:33–40.PubMedGoogle Scholar
  157. 157.
    Margolin KA, Aronson FR, Sznol M, et al. 1991. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin’s disease and non-Hodgkin’s lymphoma. J Immunother 10:214–220.PubMedGoogle Scholar
  158. 158.
    Lim SH, Worman CP, Callaghan T, Jewell A, Smith MP, Goldstone AH. 1991. Continuous intravenous infusion of high dose recombinant interleukin-2 for advanced lymphomas — a phase II study. Leuk Res 15:435–440.PubMedGoogle Scholar
  159. 159.
    Bernstein ZP, Vaickus L, Friedman N, et al. 1991. Interleukin-2 and lymphokine-activated killer cell therapy of non-Hodgkin’s lymphoma and Hodgkin’s disease. J Immunother 10: 141–146.PubMedGoogle Scholar
  160. 160.
    Gisselbrecht C, Maraninchi D, Pico JL, et al. 1994. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 83:2081–2085.PubMedGoogle Scholar
  161. 161.
    Klingemann H-G, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, Reece DE, Shepherd JD, Phillips GL. 1991. Treatment with recombinant interferon (α-2B) early after bone marrow transplantation in patients at high risk for relapse. Blood 78:3306–3311.PubMedGoogle Scholar
  162. 162.
    Schenkein DP, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao JL, Miller KB. 1994. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hemato poietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin’s disease. J Clin Oncol 12:2423–2431.PubMedGoogle Scholar
  163. 163.
    Beyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A. 1995. Immunotherapy with interleukin-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 16:283–288.Google Scholar
  164. 164.
    Brenner MK. 1991. Interleukin-2 and the treatment of leukemia and lymphoma. Leuk Lymphoma 5:77–83.Google Scholar
  165. 165.
    Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T, Paul WE. 1982. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med 155:914–919.PubMedGoogle Scholar
  166. 166.
    Paul WE. 1984. Nomenclature of lymphokines which regulate B-lymphocytes. Mol Immunol 21:343–348.PubMedGoogle Scholar
  167. 167.
    Oliver K, Noelle RJ, Uhr JW, Krammer PH, Vitetta ES. 1985. B-cell growth factor (B-cell growth factor 1 or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U.S.A. 82:2465–2469.PubMedGoogle Scholar
  168. 168.
    Coffman RL, Ohara J, Bond MW, Carty J, Zlotnick A, Paul WE. 1986. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 136: 4538–4544.PubMedGoogle Scholar
  169. 169.
    Jabara HH, Fu SM, Geha RS, Vercelli D. 1990. CD40 and IgE: synergism between anti-CD-40 mAb and IL-4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 172:1861–1867.PubMedGoogle Scholar
  170. 170.
    Llorente L, Mitjavila F, Crevon M-C, Galanaud P. 1990. Dual effects of interleukin-4 on antigen-activated human B cells: induction of proliferation and inhibition of interleukin 2-dependent differentation. Eur J Immunol 20:1887–1894.PubMedGoogle Scholar
  171. 171.
    Karray S, Defrance T, Merle-Beral H, Banchereau J, Debre P, Galanaud P. 1988. Interleukin-4 inhibits the proliferation but not the differentation of activated human B cells in response to interleukin-2. J Exp Med 168:1321–1329.Google Scholar
  172. 172.
    Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. 1992. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 80:3173–3181.PubMedGoogle Scholar
  173. 173.
    Karray S, Defrance T, Merle-Beral H, Banchereau J, Debre P, Galanaud P. 1988. Interleukin-4 counteracts the interleukin-2-induced proliferation of monoclonal B cells. J Exp Med 168:85–90.PubMedGoogle Scholar
  174. 174.
    Taylor CW, Grogan TM, Salmon SE. 1990. Effects of IL-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 75:1114–1121.PubMedGoogle Scholar
  175. 175.
    Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfat M. 1992. Interleukin-4 protects chronic lymphocytic leukemic B cells from death by apopotosis and upregulates bcl-2 expression. J Exp Med 176:1319–1325.PubMedGoogle Scholar
  176. 176.
    Panayotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV. 1993. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukemia cells in vitro. Br J Haematol 85:439–445.Google Scholar
  177. 177.
    Frankfurt OS, Byrnes JJ, Villa L. In press. Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients. Leukemia Res.Google Scholar
  178. 178.
    Freimann J, Estrov Z, Itoh K, O’Brien S, Kantarjian H, Keating M, Yeomans A, Hunter C, Gutterman J, Markowitz A. 1990. Phase I studies of recombinant human interleukin-4 in patients with hematologic malignancies. Blood (Suppl 1) 76:93a. (abstract)Google Scholar
  179. 179.
    Maher D, Boyd A, McKendrick J, Begley G, Lieschke M, Green M, Fox R, Railings M, Bonnern E, Morstyn G. 1990. Rapid response of B-cell malignancies induced by interleukin-4. Blood (Suppl 1) 76:152a.Google Scholar
  180. 180.
    Makower D, Venkatraj U, Dutcher JP, Wiernik PH. In press. Occurrence of myeloma in a chronic lymphocytic leukemia patient after response to differentiation therapy with interleukin-4. Leuk Lymphoma. (abstract)Google Scholar
  181. 181.
    Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Animan KH, Schlossman SF. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147–3154.PubMedGoogle Scholar
  182. 182.
    Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED. 1987. Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584–591.PubMedGoogle Scholar
  183. 183.
    Grossbard ML, Freedman AS, Ritz J, et al. 1992. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 79:576–585.PubMedGoogle Scholar
  184. 184.
    Grossbard ML, Lambert JM, Goldmacher VS, et al. 1993. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726–737.PubMedGoogle Scholar
  185. 185.
    Scheinberg DA, Straus DJ, Yeh SD, Divgi C, Garin-Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ. 1990. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin’s lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 8:792–803.PubMedGoogle Scholar
  186. 186.
    DeNardo SJ, DeNardo GL, O’Grady LF, Hu E, Sytsma VM, Mills SL, Levy NB, Macey DJ, Miller CH, Epstein AL. 1988. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using 131I lym-1 monoclonal antibody. Int J Cancer 3(Suppl):96–101.Google Scholar
  187. 187.
    DeNardo GL, DeNardo SJ, O’Grady LF, Levy NB, Adams GP, Mills SL. 1990. Fractionated radioimmunotherapy of B-cell malignancies with 131I Lym-1. Cancer Res 50(Suppl 3):1014S–1016S.PubMedGoogle Scholar
  188. 188.
    Goldenberg DM, Horowitz JA, Sharkey RM, et al. 1991. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548–564.PubMedGoogle Scholar
  189. 189.
    Kaminski MS, Zasadny KR, Francis IR, et al. 1993. Radioimmunotherapy of B-cell lymphoma with [131I]anti-Bl (anti-CD20) antibody. N Engl J Med 329:459–465.PubMedGoogle Scholar
  190. 190.
    Kaminski MS, Zasadny KR, Francis IR, et al. 1996. Iodine-131-anti-Bl radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974–1981.PubMedGoogle Scholar
  191. 191.
    Press OW, Eary JF, Appelbaum FR, et al. 1993. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219–1224.PubMedGoogle Scholar
  192. 192.
    Davis TA, Goris ML, Trisler KD, et al. 1995. 90Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma. Blood 86(Suppl l):273a. (abstract)Google Scholar
  193. 193.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. 1990. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145:1029–1036.PubMedGoogle Scholar
  194. 194.
    Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209–1215.PubMedGoogle Scholar
  195. 195.
    Hsu FJ, Caspar CB, Kwak LW, Liles T, Czerwinski DK, Taidi B, Levy R. 1995. Results of a clinical trial of idiotype specific vaccine therapy for B cell lymphoma. Blood 86(Suppl 1): 273a. (abstract)Google Scholar
  196. 196.
    Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58.PubMedGoogle Scholar
  197. 197.
    White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL, Collins HA, Royston I. 1996. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium 90 anti-indiotype monoclonal antibodies. Blood 87:3640–3649.PubMedGoogle Scholar
  198. 198.
    Storb R, Deeg HJ, Fisher L, et al. 1988. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 71:293–298.PubMedGoogle Scholar
  199. 199.
    Chao NS, Schmidt G, Niland J, 1993. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prophylaxis for acute graft-versus-host disease. N Engl J Med 329:1225–1232.PubMedGoogle Scholar
  200. 200.
    Granelli-Piperno A. 1988. In situ hybridization for interleukin-2 and interleukin-2 receptor mRNA in T cells activated in the presence or absence or cyclosporin A. J Exp Med 168:1649–1655.PubMedGoogle Scholar
  201. 201.
    Redelman D. 1988. Cyclosporin A does not inhibit the PHA-stimulated increase in intracellular Ca2+ concentration but inhibits the increase in E-rosette receptor (CD2) expression and appearance of IL-2 receptors (CD25). Cytometry 9:156–162.PubMedGoogle Scholar
  202. 202.
    Hess AD, Horwitz L, Beschorner WE, Santos GW. 1985. Development of graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-la specificity, including autoreactivity. J Exp Med 161:718–724.PubMedGoogle Scholar
  203. 203.
    Hess AD, Horwitz LR, Laulis MK. 1993. Cyclosporine induced syngeneic graft-versus-host disease: recognition of self MHC class II antigens in vivo. Transplant Proc. 17:528–535.Google Scholar
  204. 204.
    Miesher PA, Favre H, Beris P. 1991. Autoimmune myelodysplasias. Semin Hematol 28:322–332.Google Scholar
  205. 205.
    Gotic M, Basara N, Rolovic Z, Boskovic D, Antunovic P, Marisavljevic D, Brkic S. 1994. Successful treatment of refractory pure red cell aplasia secondary to chronic lymphocytic leukaemia with cyclosporine A: correlation between clinical and in vitro effects. Nouv Rev Fr Hematol 36:307–309.PubMedGoogle Scholar
  206. 206.
    Wright SJ, Keating MJ. 1995. Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role? Leuk Lymphoma 20:131–137.PubMedGoogle Scholar
  207. 207.
    Kelsey PR, Schofield KP, Geary CG. 1985. Refractory idiopathic thrombocytopenic purpura treated with cyclosporine. Br J Haematol 60:197–203.PubMedGoogle Scholar
  208. 208.
    Novik Y, Oleksowicz L, Wiernik PH. In press. Therapeutic effect of cyclosporine A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukemia. Br J Haematol.Google Scholar
  209. 209.
    Cooper DL, Braverman IM, Sarris AH, Durivage HJ, Saidman BH, Davis CA, Hait WN. 1993. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 71:2335–2341.PubMedGoogle Scholar
  210. 210.
    Murayama T, Imoto S, Takahashi T, Ito M, Matozaki S, Nakagawa T. 1992. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. Cancer 69:2567–2573.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1999

Authors and Affiliations

  • Janice P. Dutcher
  • Peter H. Wiernik

There are no affiliations available

Personalised recommendations